SNO Survey on Temozolomide Use

Question Title

* 1. I am a

neuro-oncologist or medical oncologist

nurse practitioner/physician's assistant

radiation oncologist

neurosurgeon

other

Question Title

* 2. I work with

adult patients

pediatric patients

both

Question Title

* 3. I live and work

inside the US

outside the US

Question Title

* 4. It is being reported that Merck will be discontinuing most strengths of Temozolomide and is ending its Patient Assistant Program. What is/are the most common strength(s) of Temozolomide you prescribe? (Check all that apply)

Capsules 5-mg (5 count)

Capsules 5-mg (14 count)

Capsules 20-mg (5 count)

Capsules 20-mg (14 count)

Capsules 100-mg (5 count)

Capsules 100-mg (14 count)

Capsules 140-mg (5 count)

Capsules 140-mg (14 count)

Capsules 180-mg (5 count)

Capsules 180-mg (14 count)

Capsules 250-mg (5 count)

Temozolomide for injection

Question Title

* 5. Do you have patients that rely on the Patient Assistance Program?

Yes

Unsure

Question Title

* 6. Has the discontinuation been communicated to these patients by Merck?

Yes

Unsure

Question Title

* 7. Do you view there to be widely available alternatives (generics) to Temozolomide?

Yes

Unsure

Question Title

* 8. Do you anticipate further challenges for patients?

Yes

Unsure

Question Title

* 9. Is there anything else, or specific anecdotes, regarding Merck’s discontinuation of Temozolomide production that could be helpful in advocacy efforts on Capitol Hill?

Question Title

* 10. Previously, we asked SNO members about their experience with Lomustine (Gleostine) price hikes and shared this information with legislators in Washington, DC. We’re seeking to update our records in case there were recent changes in status. In the last 6 months, which of the following issues have you personally encountered in prescribing Lomustine (Gleostine) to patients? (Check all that apply)

increased staff time in securing insurance approval

insurance denial

patient complaint of increase in copay

change in therapy issue

Other (please specify)

Question Title

* 11. Is there any new information regarding pricing of Lomustine or specific anecdotes from your patient care that may be helpful in sharing with legislators on Capitol Hill who are working on the issue?